100 Columbia
Aliso Viejo, CA 92656
United States
949 521 7830
https://www.rxsight.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 374
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Ronald M. Kurtz M.D. | President, CEO & Director | 1.21M | N/D | 1963 |
Ms. Shelley B. Thunen | Chief Financial Officer | 762.22k | N/D | 1954 |
Dr. Ilya Goldshleger Ph.D. | Chief Operating Officer | 761.46k | N/D | 1975 |
Mr. Eric J. Weinberg | Chief Commercial Officer | 762.74k | N/D | 1961 |
Ms. Rebecca Williston | Vice President of Accounting & Finance | N/D | N/D | N/D |
Mr. Matt Haller Ph.D. | Chief Technology Officer | N/D | N/D | N/D |
Mr. Oliver Moravcevic | Vice President of Investor Relations | N/D | N/D | N/D |
Mr. Roy Freeman | Vice President of Marketing | N/D | N/D | N/D |
Ms. Caroline Vaughn | Vice President of Human Resources | N/D | N/D | N/D |
Mr. Scott Gaines | Senior VP of Commercial Operations & Business Process | N/D | N/D | N/D |
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
La calificación ISS Governance QuickScore de RxSight, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 5; Junta: 4; Derechos del accionista: 8; Compensación: 9.